Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists
Peptide receptor radionuclide therapy (PRRT) has over the last two decades emerged as a very promising approach to treat neuroendocrine tumors (NETs) with rapidly expanding clinical applications. By chelating a radiometal to a somatostatin receptor (SSTR) ligand, radiation can be delivered to cancer...
Na minha lista:
| Principais autores: | , , , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Frontiers Media S.A.
2022-12-01
|
| Serier: | Frontiers in Medicine |
| Fag: | |
| Online adgang: | https://www.frontiersin.org/articles/10.3389/fmed.2022.1034315/full |
| Tags: |
Ingen Tags, Vær først til at tagge denne postø!
|
